Gilbert Dialysis (FMC) is a medicare approved dialysis facility center in Gilbert, Arizona and it has 12 dialysis stations. It is located in Maricopa county at 3511 Mercy Rd Ste 101, Gilbert, AZ, 85297. You can reach out to the office of Gilbert Dialysis (FMC) at (480) 857-8338. This dialysis clinic is managed and/or owned by Fresenius Medical Care. Gilbert Dialysis (FMC) has the following ownership type - Profit. It was first certified by medicare in March, 2011. The medicare id for this facility is 032635 and it accepts patients under medicare ESRD program.
| Name | Gilbert Dialysis (FMC) |
|---|---|
| Location | 3511 Mercy Rd Ste 101, Gilbert, Arizona |
| No. of Dialysis Stations | 12 |
| Medicare ID | 032635 |
| Managed By | Fresenius Medical Care |
| Ownership Type | Profit |
| Late Shifts | No |
| 3511 Mercy Rd Ste 101, Gilbert, Arizona, 85297 | |
| (480) 857-8338 | |
News Archive
For many patients with advanced breast cancer, the cancer drug Herceptin (trastuzumab) has offered new hope when traditional cancer drugs failed to work, shrinking tumors and sending some patients into remission.
A technology created by University of Rochester physicians and scientists that has helped boost the eyesight of patients to unprecedented levels is now more widely available, thanks to approval by the U.S. Food and Drug Administration.
Investigators at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed) have identified a novel disease mechanism underlying rheumatoid arthritis that may open the door to new therapies for this and other debilitating autoimmune disorders.
Franziska Michor was picked as the winner of a Creative Promise Prize in Biomedical Science for her research that fuses evolutionary biology, mathematics, and clinical research toward a better understanding of cancer genesis and treatments.
A dangerous drug-resistant bacterium is becoming more prevalent in many intensive care units, according to an article in the Feb. 1 issue of Clinical Infectious Diseases, now available online.
› Verified 4 days ago
| NPI Number | 1407176068 |
| Organization Name | Fresenius Medical Care Gilbert |
| Doing Business As | Bio-medical Applications Of Arizona, Llc |
| Address | 3511 S Mercy Rd Gilbert, Arizona, 85297 |
| Phone Number | (480) 857-8338 |
News Archive
For many patients with advanced breast cancer, the cancer drug Herceptin (trastuzumab) has offered new hope when traditional cancer drugs failed to work, shrinking tumors and sending some patients into remission.
A technology created by University of Rochester physicians and scientists that has helped boost the eyesight of patients to unprecedented levels is now more widely available, thanks to approval by the U.S. Food and Drug Administration.
Investigators at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed) have identified a novel disease mechanism underlying rheumatoid arthritis that may open the door to new therapies for this and other debilitating autoimmune disorders.
Franziska Michor was picked as the winner of a Creative Promise Prize in Biomedical Science for her research that fuses evolutionary biology, mathematics, and clinical research toward a better understanding of cancer genesis and treatments.
A dangerous drug-resistant bacterium is becoming more prevalent in many intensive care units, according to an article in the Feb. 1 issue of Clinical Infectious Diseases, now available online.
› Verified 4 days ago
| Dialysis patients with Hemoglobin data | 36 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 14 |
News Archive
For many patients with advanced breast cancer, the cancer drug Herceptin (trastuzumab) has offered new hope when traditional cancer drugs failed to work, shrinking tumors and sending some patients into remission.
A technology created by University of Rochester physicians and scientists that has helped boost the eyesight of patients to unprecedented levels is now more widely available, thanks to approval by the U.S. Food and Drug Administration.
Investigators at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed) have identified a novel disease mechanism underlying rheumatoid arthritis that may open the door to new therapies for this and other debilitating autoimmune disorders.
Franziska Michor was picked as the winner of a Creative Promise Prize in Biomedical Science for her research that fuses evolutionary biology, mathematics, and clinical research toward a better understanding of cancer genesis and treatments.
A dangerous drug-resistant bacterium is becoming more prevalent in many intensive care units, according to an article in the Feb. 1 issue of Clinical Infectious Diseases, now available online.
› Verified 4 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 84 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 649 |
| Percentage of adult patients getting regular hemodialysis at the center | 97 |
News Archive
For many patients with advanced breast cancer, the cancer drug Herceptin (trastuzumab) has offered new hope when traditional cancer drugs failed to work, shrinking tumors and sending some patients into remission.
A technology created by University of Rochester physicians and scientists that has helped boost the eyesight of patients to unprecedented levels is now more widely available, thanks to approval by the U.S. Food and Drug Administration.
Investigators at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed) have identified a novel disease mechanism underlying rheumatoid arthritis that may open the door to new therapies for this and other debilitating autoimmune disorders.
Franziska Michor was picked as the winner of a Creative Promise Prize in Biomedical Science for her research that fuses evolutionary biology, mathematics, and clinical research toward a better understanding of cancer genesis and treatments.
A dangerous drug-resistant bacterium is becoming more prevalent in many intensive care units, according to an article in the Feb. 1 issue of Clinical Infectious Diseases, now available online.
› Verified 4 days ago
| Adult patients getting regular peritoneal dialysis at the center | 56 |
| Adult patient months included in Kt/V greater than or equal to 1.7 | 422 |
| Percentage of adult patients getting regular peritoneal dialysis at the center | 91 |
News Archive
For many patients with advanced breast cancer, the cancer drug Herceptin (trastuzumab) has offered new hope when traditional cancer drugs failed to work, shrinking tumors and sending some patients into remission.
A technology created by University of Rochester physicians and scientists that has helped boost the eyesight of patients to unprecedented levels is now more widely available, thanks to approval by the U.S. Food and Drug Administration.
Investigators at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed) have identified a novel disease mechanism underlying rheumatoid arthritis that may open the door to new therapies for this and other debilitating autoimmune disorders.
Franziska Michor was picked as the winner of a Creative Promise Prize in Biomedical Science for her research that fuses evolutionary biology, mathematics, and clinical research toward a better understanding of cancer genesis and treatments.
A dangerous drug-resistant bacterium is becoming more prevalent in many intensive care units, according to an article in the Feb. 1 issue of Clinical Infectious Diseases, now available online.
› Verified 4 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Gilbert Dialysis (FMC) with elevated calcium levels.
| Patients with hypercalcemia | 149 |
| Hypercalcemia patient months | 1190 |
| Patients with Serumphosphor | 158 |
| Patients with Serumphosphor less than 3.5 mg/dL | 6 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 26 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 29 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 26 |
| Patients with Serumphosphor greater than 7 mg/dL | 14 |
News Archive
For many patients with advanced breast cancer, the cancer drug Herceptin (trastuzumab) has offered new hope when traditional cancer drugs failed to work, shrinking tumors and sending some patients into remission.
A technology created by University of Rochester physicians and scientists that has helped boost the eyesight of patients to unprecedented levels is now more widely available, thanks to approval by the U.S. Food and Drug Administration.
Investigators at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed) have identified a novel disease mechanism underlying rheumatoid arthritis that may open the door to new therapies for this and other debilitating autoimmune disorders.
Franziska Michor was picked as the winner of a Creative Promise Prize in Biomedical Science for her research that fuses evolutionary biology, mathematics, and clinical research toward a better understanding of cancer genesis and treatments.
A dangerous drug-resistant bacterium is becoming more prevalent in many intensive care units, according to an article in the Feb. 1 issue of Clinical Infectious Diseases, now available online.
› Verified 4 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 72 |
| Patient months included in arterial venous fistula and catheter summaries | 357 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 79 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 8 |
News Archive
For many patients with advanced breast cancer, the cancer drug Herceptin (trastuzumab) has offered new hope when traditional cancer drugs failed to work, shrinking tumors and sending some patients into remission.
A technology created by University of Rochester physicians and scientists that has helped boost the eyesight of patients to unprecedented levels is now more widely available, thanks to approval by the U.S. Food and Drug Administration.
Investigators at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed) have identified a novel disease mechanism underlying rheumatoid arthritis that may open the door to new therapies for this and other debilitating autoimmune disorders.
Franziska Michor was picked as the winner of a Creative Promise Prize in Biomedical Science for her research that fuses evolutionary biology, mathematics, and clinical research toward a better understanding of cancer genesis and treatments.
A dangerous drug-resistant bacterium is becoming more prevalent in many intensive care units, according to an article in the Feb. 1 issue of Clinical Infectious Diseases, now available online.
› Verified 4 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 93 |
| Hospitalization Rate in facility | 242.7 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 406.4 |
| Hospitalization Rate: Lower Confidence Limit | 149 |
News Archive
For many patients with advanced breast cancer, the cancer drug Herceptin (trastuzumab) has offered new hope when traditional cancer drugs failed to work, shrinking tumors and sending some patients into remission.
A technology created by University of Rochester physicians and scientists that has helped boost the eyesight of patients to unprecedented levels is now more widely available, thanks to approval by the U.S. Food and Drug Administration.
Investigators at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed) have identified a novel disease mechanism underlying rheumatoid arthritis that may open the door to new therapies for this and other debilitating autoimmune disorders.
Franziska Michor was picked as the winner of a Creative Promise Prize in Biomedical Science for her research that fuses evolutionary biology, mathematics, and clinical research toward a better understanding of cancer genesis and treatments.
A dangerous drug-resistant bacterium is becoming more prevalent in many intensive care units, according to an article in the Feb. 1 issue of Clinical Infectious Diseases, now available online.
› Verified 4 days ago
The rate of readmission show you whether patients who were being treated regularly at Gilbert Dialysis (FMC) were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 24 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 35.2 |
| Readmission Rate: Lower Confidence Limit | 15.1 |
News Archive
For many patients with advanced breast cancer, the cancer drug Herceptin (trastuzumab) has offered new hope when traditional cancer drugs failed to work, shrinking tumors and sending some patients into remission.
A technology created by University of Rochester physicians and scientists that has helped boost the eyesight of patients to unprecedented levels is now more widely available, thanks to approval by the U.S. Food and Drug Administration.
Investigators at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed) have identified a novel disease mechanism underlying rheumatoid arthritis that may open the door to new therapies for this and other debilitating autoimmune disorders.
Franziska Michor was picked as the winner of a Creative Promise Prize in Biomedical Science for her research that fuses evolutionary biology, mathematics, and clinical research toward a better understanding of cancer genesis and treatments.
A dangerous drug-resistant bacterium is becoming more prevalent in many intensive care units, according to an article in the Feb. 1 issue of Clinical Infectious Diseases, now available online.
› Verified 4 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Gilbert Dialysis (FMC) get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| SIR: Upper Confidence Limit | .69 |
News Archive
For many patients with advanced breast cancer, the cancer drug Herceptin (trastuzumab) has offered new hope when traditional cancer drugs failed to work, shrinking tumors and sending some patients into remission.
A technology created by University of Rochester physicians and scientists that has helped boost the eyesight of patients to unprecedented levels is now more widely available, thanks to approval by the U.S. Food and Drug Administration.
Investigators at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed) have identified a novel disease mechanism underlying rheumatoid arthritis that may open the door to new therapies for this and other debilitating autoimmune disorders.
Franziska Michor was picked as the winner of a Creative Promise Prize in Biomedical Science for her research that fuses evolutionary biology, mathematics, and clinical research toward a better understanding of cancer genesis and treatments.
A dangerous drug-resistant bacterium is becoming more prevalent in many intensive care units, according to an article in the Feb. 1 issue of Clinical Infectious Diseases, now available online.
› Verified 4 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Gilbert Dialysis (FMC)'s rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 75 |
| Transfusion Rate in facility | 42.9 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 114.4 |
| Transfusion Rate: Lower Confidence Limit | 18.2 |
News Archive
For many patients with advanced breast cancer, the cancer drug Herceptin (trastuzumab) has offered new hope when traditional cancer drugs failed to work, shrinking tumors and sending some patients into remission.
A technology created by University of Rochester physicians and scientists that has helped boost the eyesight of patients to unprecedented levels is now more widely available, thanks to approval by the U.S. Food and Drug Administration.
Investigators at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed) have identified a novel disease mechanism underlying rheumatoid arthritis that may open the door to new therapies for this and other debilitating autoimmune disorders.
Franziska Michor was picked as the winner of a Creative Promise Prize in Biomedical Science for her research that fuses evolutionary biology, mathematics, and clinical research toward a better understanding of cancer genesis and treatments.
A dangerous drug-resistant bacterium is becoming more prevalent in many intensive care units, according to an article in the Feb. 1 issue of Clinical Infectious Diseases, now available online.
› Verified 4 days ago
The rate of mortality show you whether patients who were being treated regularly at Gilbert Dialysis (FMC) lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 478 |
| Mortality Rate in facility | 16.1 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 21.7 |
| Mortality Rate: Lower Confidence Limit | 11.7 |
News Archive
For many patients with advanced breast cancer, the cancer drug Herceptin (trastuzumab) has offered new hope when traditional cancer drugs failed to work, shrinking tumors and sending some patients into remission.
A technology created by University of Rochester physicians and scientists that has helped boost the eyesight of patients to unprecedented levels is now more widely available, thanks to approval by the U.S. Food and Drug Administration.
Investigators at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed) have identified a novel disease mechanism underlying rheumatoid arthritis that may open the door to new therapies for this and other debilitating autoimmune disorders.
Franziska Michor was picked as the winner of a Creative Promise Prize in Biomedical Science for her research that fuses evolutionary biology, mathematics, and clinical research toward a better understanding of cancer genesis and treatments.
A dangerous drug-resistant bacterium is becoming more prevalent in many intensive care units, according to an article in the Feb. 1 issue of Clinical Infectious Diseases, now available online.
› Verified 4 days ago
Mesa Dialysis Center (FMC) Location: 1525 N Gilbert Rd Ste 121, Gilbert, Arizona, 85234 Phone: (480) 497-1127 |
Southwest Kidney Dialysis - Gilbert (DVA) Location: 5222 E Baseline Rd Ste 104, Gilbert, Arizona, 85234 Phone: (480) 832-6996 |
News Archive
For many patients with advanced breast cancer, the cancer drug Herceptin (trastuzumab) has offered new hope when traditional cancer drugs failed to work, shrinking tumors and sending some patients into remission.
A technology created by University of Rochester physicians and scientists that has helped boost the eyesight of patients to unprecedented levels is now more widely available, thanks to approval by the U.S. Food and Drug Administration.
Investigators at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed) have identified a novel disease mechanism underlying rheumatoid arthritis that may open the door to new therapies for this and other debilitating autoimmune disorders.
Franziska Michor was picked as the winner of a Creative Promise Prize in Biomedical Science for her research that fuses evolutionary biology, mathematics, and clinical research toward a better understanding of cancer genesis and treatments.
A dangerous drug-resistant bacterium is becoming more prevalent in many intensive care units, according to an article in the Feb. 1 issue of Clinical Infectious Diseases, now available online.
› Verified 4 days ago